STOCK TITAN

Lucid Diagnostics Inc. Stock Price, News & Analysis

LUCD Nasdaq

Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.

Lucid Diagnostics Inc. (LUCD) delivers innovative solutions for early esophageal cancer detection through its EsoGuard® DNA test and EsoCheck® cell collection technology. This news hub provides investors and healthcare professionals with essential updates on the company's advancements in noninvasive cancer screening.

Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships. Our curated collection includes updates on Medicare coverage expansions, new patent approvals, and validation studies supporting the EsoGuard test's clinical utility in GERD patients.

Key updates focus on commercial adoption progress, laboratory accreditations, and peer-reviewed research publications. Track developments in Lucid's reimbursement strategies and technological enhancements to its molecular diagnostic platform.

Bookmark this page for direct access to official announcements about product innovations, management team updates, and scientific presentations. Stay informed about Lucid's role in transforming esophageal cancer prevention through cutting-edge diagnostic solutions.

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD) will participate in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025.

Dennis McGrath, Lucid's Chief Financial Officer, will hold one-on-one investor meetings during the conference; investors should contact their Maxim representative to schedule meetings. Registration and event details are available through the Maxim Growth Summit event page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD) has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs. Scelfo, a veteran with over 25 years of experience in healthcare policy and market access, will focus on expanding insurance coverage and patient access for the company's EsoGuard® Esophageal DNA Test.

The appointment comes at a crucial time following a positive MolDX CAC meeting that suggests Medicare coverage is approaching. Scelfo's previous experience includes leadership roles at ClearNote Health, CareDx, Hologic, and other prominent healthcare companies. She will leverage her expertise to strengthen Lucid's market access infrastructure and accelerate commercial coverage expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has completed its previously announced public offering. The company successfully sold 28,750,000 shares of common stock at $1.00 per share, which includes 3,750,000 shares from the full exercise of the underwriters' option.

The offering generated net proceeds of approximately $26.9 million, after deducting underwriting discounts, commissions, and estimated expenses. The funds will be used for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC as co-manager.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
Rhea-AI Summary

Lucid Diagnostics (NASDAQ: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), has announced the pricing of its public offering of 25 million shares of common stock at $1.00 per share.

The company expects to raise approximately $25.0 million in gross proceeds, with an additional 30-day option granted to underwriters to purchase up to 3.75 million additional shares. The offering, managed by Canaccord Genuity LLC and BTIG, LLC as joint bookrunners, is expected to close around September 11, 2025. Proceeds will be used for working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.69%
Tags
-
Rhea-AI Summary

Lucid Diagnostics (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), has announced plans for an underwritten public offering of common stock. The offering includes a 30-day option for underwriters to purchase additional shares.

The offering will be managed by Canaccord Genuity LLC and BTIG, LLC as joint bookrunners, with Maxim Group LLC as co-manager. Proceeds will support working capital and general corporate purposes. The offering will be made under an effective S-3 shelf registration statement, with timing, size, and terms subject to market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.69%
Tags
-
Rhea-AI Summary

Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ:PAVM), has scheduled an investor conference call for Monday, September 8, 2025, at 8:30 AM ET.

The call will discuss the September 4 MolDX Contractor Advisory Committee (CAC) meeting regarding the reconsideration of Local Coverage Determination (LCD) L39256 for Lucid's EsoGuard® Esophageal DNA Test. Investors can join via webcast or dial in using 1-800-836-8184 (US) or 1-646-357-8785 (international). A 90-day replay will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences clinical trial
Rhea-AI Summary

Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ:PAVM), announced its participation in the upcoming Cantor Global Healthcare Conference 2025.

Chairman and CEO Lishan Aklog, M.D. will engage in a fireside chat on September 5, 2025, at 8:35 AM EDT in New York. The 30-minute presentation will be available via webcast, with a replay accessible through the company's Investor Relations website for 30 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
conferences
-
Rhea-AI Summary

PAVmed (Nasdaq: PAVM) has signed a non-binding letter of intent with Duke University to license groundbreaking endoscopic imaging technology through a new subsidiary. The technology combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT) to identify and treat esophageal precancer during upper endoscopy.

The technology, developed by Duke's Dr. Adam Wax in partnership with Dr. Nicholas Shaheen, has demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes. This innovative approach could replace traditional biopsies, enabling real-time detection and immediate treatment during the same endoscopic procedure.

Under the proposed agreement, PAVmed's subsidiary will receive exclusive worldwide license rights to the intellectual property. The company expects this technology to complement its EsoGuard diagnostic platform and attract strategic interest from endoscopic ablation companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary

PAVmed (NASDAQ: PAVM) reported its Q2 2025 financial results and business updates. Key highlights include Lucid Diagnostics processing 2,756 EsoGuard® tests with revenue of $1.2 million. The company reported a GAAP net loss of $13.3 million, or $(0.74) per share.

Significant developments include Lucid securing a CAC meeting for Medicare LCD coverage, strengthening its balance sheet with a $16.1 million public offering, and initiating testing under its first positive commercial insurance coverage with Highmark Blue Cross Blue Shield. Veris Health completed $2.5 million direct equity financing and established a strategic partnership with Ohio State's James Cancer Hospital.

The company ended Q2 2025 with cash and equivalents of $4.0 million, compared to $1.2 million at the end of 2024. Operating expenses were $4.7 million, including $0.2 million in stock-based compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD) reported its Q2 2025 financial results, highlighting $1.2 million in revenue from 2,756 processed EsoGuard® tests. The company strengthened its balance sheet through a public offering, netting $16.1 million and ending Q2 with over $30 million in proforma cash, extending runway into 2026.

Key developments include a scheduled Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 for Medicare coverage consideration, initiation of testing under Highmark Blue Cross Blue Shield coverage, and a partnership with Hoag healthcare network. The company reported a GAAP net loss of $7.9 million ($0.08 per share) and non-GAAP adjusted loss of $9.9 million ($0.10 per share) for Q2 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags

FAQ

What is the current stock price of Lucid Diagnostics (LUCD)?

The current stock price of Lucid Diagnostics (LUCD) is $1.18 as of October 17, 2025.

What is the market cap of Lucid Diagnostics (LUCD)?

The market cap of Lucid Diagnostics (LUCD) is approximately 125.3M.
Lucid Diagnostics Inc.

Nasdaq:LUCD

LUCD Rankings

LUCD Stock Data

125.33M
91.03M
34.55%
18.87%
5.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK